These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 39049086)

  • 1. Effect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy.
    Zhu T; Ye Z; Song J; Zhang J; Zhao Y; Xu F; Wang J; Huang X; Gao B; Li F
    Cardiovasc Diabetol; 2024 Jul; 23(1):273. PubMed ID: 39049086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farrerol Alleviates Diabetic Cardiomyopathy by Regulating AMPK-Mediated Cardiac Lipid Metabolic Pathways in Type 2 Diabetic Rats.
    Tu J; Liu Q; Sun H; Gan L
    Cell Biochem Biophys; 2024 Sep; 82(3):2427-2437. PubMed ID: 38878100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
    Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
    J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-
    Liu L; Luo H; Liang Y; Tang J; Shu Y
    Comput Math Methods Med; 2022; 2022():3293054. PubMed ID: 35096128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
    El-Shafey M; El-Agawy MSE; Eldosoky M; Ebrahim HA; Elsherbini DMA; El-Sherbiny M; Asseri SM; Elsherbiny NM
    Front Endocrinol (Lausanne); 2022; 13():862394. PubMed ID: 35370937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIRT6‑specific inhibitor OSS‑128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress.
    Huang Y; Zhang J; Xu D; Peng Y; Jin Y; Zhang L
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The investigation of potential mechanism of Fuzhengkangfu Decoction against Diabetic myocardial injury based on a combined strategy of network pharmacology, transcriptomics, and experimental verification.
    Li M; Chen L; Liu X; Wu Y; Chen X; Chen H; Zhong Y; Xu Y
    Biomed Pharmacother; 2024 Aug; 177():117048. PubMed ID: 38959606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats.
    El-Sayed N; Mostafa YM; AboGresha NM; Ahmed AAM; Mahmoud IZ; El-Sayed NM
    Chem Biol Interact; 2021 Sep; 347():109617. PubMed ID: 34391751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of resveratrol on regulation on UCP2 and cardiac function in diabetic rats.
    Diao J; Wei J; Yan R; Fan G; Lin L; Chen M
    J Physiol Biochem; 2019 Feb; 75(1):39-51. PubMed ID: 30225723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrine pretreatment improves cardiac function in rats with diabetic cardiomyopathy via suppressing ROS/TLR-4 signaling pathway.
    Liu ZW; Wang JK; Qiu C; Guan GC; Liu XH; Li SJ; Deng ZR
    Acta Pharmacol Sin; 2015 Mar; 36(3):323-33. PubMed ID: 25619390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of NLRP3 gene knockdown on pyroptosis and ferroptosis in diabetic cardiomyopathy injury.
    Wang J; Li Y; Li L; Liang H; Ye H; Kang P; Li Z; Yu Y; Gao Q
    BMC Cardiovasc Disord; 2024 Jul; 24(1):351. PubMed ID: 38987672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid.
    Li CJ; Lv L; Li H; Yu DM
    Cardiovasc Diabetol; 2012 Jun; 11():73. PubMed ID: 22713251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels.
    Liu DD; Liu XL; Zheng TF; Li X; Zhao YC; Pan JC; Yuan C; Wang QQ; Zhang M
    Eur J Pharmacol; 2024 Oct; 981():176875. PubMed ID: 39121982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astragalus polysaccharides inhibits cardiomyocyte apoptosis during diabetic cardiomyopathy via the endoplasmic reticulum stress pathway.
    Sun S; Yang S; An N; Wang G; Xu Q; Liu J; Mao Y
    J Ethnopharmacol; 2019 Jun; 238():111857. PubMed ID: 30959142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 mediates high-glucose-induced cardiomyocyte injury by the NADPH oxidase/reactive oxygen species pathway.
    Sun J; Zhang L; Fang J; Yang S; Chen L
    Can J Physiol Pharmacol; 2020 Nov; 98(11):826-833. PubMed ID: 32311288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic cardioptotection by tilianin and syringin in diabetic cardiomyopathy involves interaction of TLR4/NF-κB/NLRP3 and PGC1a/SIRT3 pathways.
    Yao J; Li Y; Jin Y; Chen Y; Tian L; He W
    Int Immunopharmacol; 2021 Jul; 96():107728. PubMed ID: 33971494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth differentiation factor 11 regulates high glucose-induced cardiomyocyte pyroptosis and diabetic cardiomyopathy by inhibiting inflammasome activation.
    Zhang J; Wang G; Shi Y; Liu X; Liu S; Chen W; Ning Y; Cao Y; Zhao Y; Li M
    Cardiovasc Diabetol; 2024 May; 23(1):160. PubMed ID: 38715043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.